Lixisenatide: Evidence for its potential use in the treatment of type 2 diabetes

Core Evidence

Volumn 6, Issue , 2011, Pages 67-79

  Barnett, Anthony H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Combination therapy; GETGOAL program; GLP 1 receptor agonist; Insulin; Lixisenatide; Postprandial plasma glucose; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PARACETAMOL; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; RISK ASSESSMENT; VOMITING; WEIGHT REDUCTION;

EID: 84866545755     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S15525     Document Type: Article

References (28)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
2. Department of Health. Turning the corner: Improving diabetes care. 2006. Available from: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/ @en/documents/digitalasset/dh-4136011.pdf. Accessed August 11, 2011.
3. International Diabetes Federation. Diabetes Atlas, 4th Edition. 2009. Available from: http://www.diabetesatlas.org/content/europe. Accessed August 11, 2011.
4. National Health Service. The Information Centre. Prevalence. Quality and outcomes framework (QOF) for April 2009 - March 2010, England. Available from: http://www.ic.nhs.uk/webfiles/QOF/2009-10/Prevalence%20tables/ QOF0910-National-Prevalence.xls. Accessed August 11, 2011.
5. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
6. National Institute for Health and Clinical Excellence. Type 2 diabetes: The management of type 2 diabetes. NICE clinical guideline 87. May, 2009. Available from: http://www.nice.org.uk/nicemedia/pdf/CG87 NICEGuideline.pdf. Accessed August 11, 2011.
7. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association, European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17-30.
8. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
9. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 1994;53:2181-2189.
10. Thorkildsen C, Neve S, Larsen BD, Meier E, Pedersen JS. Glucagon-like peptide 1 receptor agonist ZP10 A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003;307:490-496.
11. Werner U, Haschke H, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164:58-64.
12. Haschke G, Haag-Diergarten S, Werner U, Kramer W, Herling AW. The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats - an isolated perfused pancreas study. Diabetologia. 2006;49:400-401.
13. Moore MC, Werner U, Smith MS, Rodewald TD, Cherrington AD. Effect of the glucagon-like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog. Diabetologia. 2007;50:S242.
14. Werner U, Gerlach M, Hofmann M, Herling AW. Treatment of obese Zucker diabetic fatty rats with novel GLP-1 receptor agonist AVE0010 improves oral glucose tolerance and glycaemic control without risk of hypoglycaemia. Diabetologia. 2006;49 Suppl 1:398-399.
15. Werner U, Vandewalle B, Kerr Conte J, Pattou F, Pruniaux M, Herling AW. The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves β-cell function in human pancreatic islets. Diabetes. 2008;57:3-4.
16. Tews D, Werner U, Eckel J. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res. 2008;40:172-180.
17. Distiller LA, Ruus P; on behalf of the ACT6011 Study Group. Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients. Diabetes. 2008;57 Suppl 1:A154-155.
18. Becker RH, Ruus P, Liu Y-H, Kapitza C. Restoration of insulin release with lixisenatide in patients with type 2 diabetes. Diabetologica. 2010;53 Suppl 1:S339.
19. Liu Y-H, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment. Abstract 557-P presented at the 69th Scientific Sessions of the American Diabetes Association, June 5-9, 2009, New Orleans, LA.
20. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Dosedependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27:1024-1032.
21. Gerich JE, Fonseca VA, Alvardo-Ruiz R, et al. Monotherapy with GLP-1 receptor agonist, lixisenatide, significantly improves glycaemic control in type 2 diabetic patients. Diabetologia. 2010;53 Suppl 1:S330.
22. Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once-daily vs exenatide twice-daily in type 2 DM inadequately controlled on metformin (GetGoal-X). Abstract 0033-LB presented at the 71st Scientific Sessions of the American Diabetes Association, June 24-28, 2011, San Diego, CA.
23. Sanofi-Aventis press release, 12 April 2011. Lixisenatide significantly reduces HbA1c without increasing hypoglycemia in patients uncontrolled on sulfonylureas (GETGOAL-S). Available from: http://en.sanofi-aventis.com/ binaries/20110412-LIXI-GETGOAL-S-EN-tcm28-31652.pdf. Accessed August 11, 2011.
24. Seino Y, Min K, Niemoeller E, Takami A. Lixisenatide significantly improves glycemic control in Asian patients with T2DM insufficiently controlled on basal insulin ± SU. Abstract 0278-OR presented at the 71st Scientific Sessions of the American Diabetes Association, June 24-28, 2011, San Diego, CA.
25. Sanofi-Aventis press release, 31 May 2011. Sanofi GetGoal program on Lyxumia®, as an add-on to basal insulin, shows significant positive phase III results. Available from: http://en.sanofi.com/binaries/20110531-LYXUMIA-en- tcm28-32746.pdf. Accessed August 11, 2011.
26. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96:1695-1702.
27. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
28. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med. 2011;154:103-112.